Hôpital Beaujon

Running trials

• Not yet recruiting

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source

• Not yet recruiting

  Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)

  NCT07890012· Hospices Civils de Lyon· Source

• Not yet recruiting

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

  NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Not yet recruiting

  Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

  NCT07547033· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

  NCT07654283· Phase 2· AusperBio Therapeutics Inc.· Source

• Recruiting

  PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.

  2024-519753-11-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  LEOPARD Prospective Validation Cohort 1

  NCT06723275· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

  NCT07616687· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Not yet recruiting

  Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial

  NCT07497750· University Hospital, Toulouse· Source

• Recruiting

  Multicenter Study for External Validation of the TB-NET Score

  NCT07903532· Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz· Source

• Recruiting

  Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

  NCT07585890· University Medical Center Groningen· Source

• Not yet recruiting

  Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

  NCT07337447· Phase 2· Hospices Civils de Lyon· Source

• Recruiting

  Evaluating the roLe of Multiplexed PET Imaging in the detection and staging of hepatocellulaR carcinoma and gAstro-entero-pancreatic tumors: a basket diagnostic performance study

  2024-519505-35-00· Phase 3· Centre Hospitalier Universitaire De Nantes· Source

• Recruiting

  Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

  NCT06254248· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota transplant in UC with ileo-anal anastomosis.

  NCT03524352· Phase 3· Centre Hospitalier Universitaire De Nantes· Source

• Recruiting

  Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

  NCT06990659· University Hospital, Angers· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

  NCT07044453· Phase 2/3· University Hospital, Rouen· Source

• Recruiting

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· Phase 3· AstraZeneca· Source

• Recruiting

  Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects with Chronic Hepatitis B (B-SUPREME)

  2025-521178-33-00· Phase 2· Aligos Therapeutics Inc.· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

  NCT06529718· Phase 2· UNICANCER· Source

• Active, not recruiting

  A Phase 3 Trial Comparing Whether BEM/RZR is Similar to SOF/VEL in Patients with Hepatitis C Virus Infection

  2025-521096-31-00· Phase 3· Atea Pharmaceuticals Inc.· Source

• Recruiting

  [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.

  NCT06999837· Phase 1/2· Nantes University Hospital· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Not yet recruiting

  A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

  NCT06984718· Phase 2· Akeso· Source

• Not yet recruiting

  Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial

  NCT06263816· Phase 3· University Hospital, Tours· Source

• Recruiting

  Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

  NCT06878664· Phase 3· Grupo Espanol de Tumores Neuroendocrinos· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER”

  2023-508201-25-00· Phase 2· Centre De Lutte Contre Le Cancer Eugene Marquis· Source

• Recruiting

  Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma

  NCT06551272· Phase 2· Center Eugene Marquis· Source

• Recruiting

  Effects of Metformin on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal Hypertension

  NCT06687265· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  LEOPARD Training and Validation Data Collection Study

  NCT06675604· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

  NCT06475352· Phase 2· UNICANCER· Source

• Active, not recruiting

  Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

  NCT06501625· Phase 1/2· Institut de Recherches Internationales Servier· Source

• Recruiting

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  2024-512895-36-00· Phase 3· Akero Therapeutics Inc.· Source

• Recruiting

  Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

  NCT06680232· Phase 1· Precision BioSciences, Inc.· Source

• Recruiting

  Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled trial

  2024-514633-38-00· Phase 3· Centre Hospitalier Universitaire Amiens Picardie· Source

• Recruiting

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

  NCT06427941· Phase 1/2· BeOne Medicines· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Jazz Pharmaceuticals· Source

• Recruiting

  Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

  NCT06334965· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

  NCT05895136· Phase 2· European Foundation for Study of Chronic Liver Failure· Source

• Recruiting

  A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)

  2023-505660-11-00· Phase 3· Transthera Sciences (Nanjing) Inc.· Source

• Recruiting

  Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

  NCT05300035· Phase 2· ANRS, Emerging Infectious Diseases· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

  NCT06318169· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

  2023-505141-48-00· Phase 3· Akero Therapeutics Inc.· Source

• Active, not recruiting

  BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

  NCT05911633· Terumo Europe N.V.· Source

Showing 50 of 93.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer22 recruiting
• Neuroendocrine tumours11 recruiting
• Pancreatic cancer8 recruiting
• Fatty liver disease (MASLD/MASH)6 recruiting
• Liver cirrhosis6 recruiting
• Hepatitis B4 recruiting
• Colorectal cancer3 recruiting
• Crohn's disease3 recruiting
• Ulcerative colitis3 recruiting
• Childhood cancers2 recruiting
• High blood pressure2 recruiting
• Primary biliary cholangitis2 recruiting
• Gastric and oesophageal cancer1 recruiting
• HIV1 recruiting
• Lung cancer1 recruiting
• Sickle cell disease1 recruiting

Closed trials

• Completed

  Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

  NCT06855056· European Foundation for Study of Chronic Liver Failure· Source

• Completed

  A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

  2023-509027-41-00· Phase 1· Glaxosmithkline Research & Development Limited· Source

• Completed

  Open-Label Study of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab in Subjects with Chronic HBV Infection

  NCT06245291· Phase 2· Arbutus Biopharma Inc.· Source

• Completed

  Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7.

  NCT04777851· Phase 3· Translational Research In Oncology· Source

• Completed

  A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain

  2022-501310-57-00· Phase 2· Organon LLC· Source

• Active, not recruiting

  A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

  NCT06246643· Phase 2· Bayer· Source

• Active, not recruiting

  Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

  NCT05883644· Phase 3· AstraZeneca· Source

• Completed

  A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

  NCT05612581· Phase 1/2· Vir Biotechnology, Inc.· Source

• Completed

  Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

  NCT05665348· Phase 2/3· Federation Francophone de Cancerologie Digestive· Source

• Completed

  Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE)

  2024-511538-11-00· Phase 2· Institut Gustave Roussy· Source

• Completed

  Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER

  NCT05448677· Phase 2· Centre Hospitalier Universitaire De Grenoble· Source

• Terminated

  Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

  NCT05516498· Phase 2· AstraZeneca· Source

• Completed

  International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

  NCT05387811· Azienda Ospedaliera di Padova· Source

• Completed

  An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants

  NCT05275023· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

  NCT05123599· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients

  NCT04802954· IHU Strasbourg· Source

• Completed

  Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

  NCT04903626· Phase 3· AbbVie· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

  NCT04585789· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

  NCT04567615· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

  NCT04696055· Phase 2· Bayer· Source

• Completed

  Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

  NCT04424303· Pfizer· Source

• Completed

  A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

  NCT04535544· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

  NCT04439539· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)

  NCT04483726· University Hospital, Montpellier· Source

• Completed

  A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

  NCT04225715· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

  NCT04039607· Phase 3· Bristol-Myers Squibb· Source

• Completed

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

  NCT04003636· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

  NCT03838263· Phase 2· UNICANCER· Source

• Completed

  Microvesicles and Monocytes to Predict Mortality of Patients with Cirrhosis

  NCT03837444· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  "Impact of Pelvic Floor Prehabilitation Using Biofeedback on the Severity of the Low Anterior Resection Syndrome in Patients Undergoing a Total Mesorectal Excision for Rectal Cancer"

  NCT03876561· Nantes University Hospital· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Kyntra Bio· Source

• Completed

  Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality

  NCT03702920· Phase 3· Instituto Grifols S.A.· Source

• Completed

  Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

  NCT04069468· Boston Scientific Corporation· Source

• Completed

  A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

  NCT03656536· Phase 3· Incyte Corp.· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

  NCT03778957· Phase 3· AstraZeneca· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· Phase 3· AbbVie· Source

• Completed

  A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Resection or Ablation

  2023-508726-10-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma

  NCT02799212· Phase 3· Hospices Civils de Lyon· Source

• Completed

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· Phase 3· BeiGene· Source

• Completed

  Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

  NCT02820857· Phase 2· Hospices Civils de Lyon· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Alfasigma S.p.A.· Source

• Completed

  Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

  NCT02676349· Phase 2· Institut de Cancérologie de Lorraine· Source

• Completed

  Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

  NCT02738125· AbbVie· Source

• Completed

  Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy

  NCT02514278· Phase 3· University Hospital, Bordeaux· Source

• Completed

  A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

  NCT02508467· Phase 1· Blueprint Medicines Corporation· Source

Showing 50 of 51.

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer104 works · 54 trials
• Fatty liver disease (MASLD/MASH)34 works · 11 trials
• Neuroendocrine tumours16 works · 15 trials
• Hepatitis B9 works · 13 trials
• Gaucher disease3 works · 0 trials